Systematic review of clinical drug development activities for neuroblastoma from 2011 to 2020

Understanding the landscape of clinical trials for patients with neuroblastoma may inform efforts to improve drug development.

[1]  N. Scobie,et al.  When Innovation and Commercialization Collide: A Patient Advocate View in Neuroblastoma. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Kearns,et al.  Intercontinental collaboration in clinical trials for children and adolescents with cancer—A systematic review by ACCELERATE , 2021, Cancer medicine.

[3]  K. Norga,et al.  Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. , 2021, European journal of cancer.

[4]  A. Naranjo,et al.  Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Xingyu Zhang,et al.  Updated analysis of pediatric clinical studies registered in ClinicalTrials.gov, 2008–2019 , 2021, BMC Pediatrics.

[6]  R. Bagatell,et al.  Trends in conditional survival and predictors of late death in neuroblastoma , 2020, Pediatric blood & cancer.

[7]  F. Speleman,et al.  Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. , 2020, European journal of cancer.

[8]  F. Bourgeois,et al.  Sponsorship of oncology clinical trials in the United States according to age of eligibility , 2020, Cancer medicine.

[9]  A. Naranjo,et al.  Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. , 2019, JAMA.

[10]  S. Deyev,et al.  Neuroblastoma Origin and Therapeutic Targets for Immunotherapy , 2018, Journal of immunology research.

[11]  J. Stebbing,et al.  Targeted cancer therapies: Oral health care implications. , 2018, The Journal of the American Dental Association (1939).

[12]  F. Berthold,et al.  Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project , 2017, Expert opinion on drug discovery.

[13]  S. Pfister,et al.  Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective , 2017, Nature Reviews Clinical Oncology.

[14]  Gudrun Schleiermacher,et al.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Connor,et al.  The platform trial: an efficient strategy for evaluating multiple treatments. , 2015, JAMA.

[16]  S. Cohn,et al.  Second malignancies in patients with neuroblastoma: The effects of risk‐based therapy , 2015, Pediatric blood & cancer.

[17]  C. Tudur Smith,et al.  A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov , 2014, Orphanet Journal of Rare Diseases.

[18]  Kevin C Oeffinger,et al.  Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Berthold,et al.  Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Caron,et al.  Neuroblastoma: biology, prognosis, and treatment. , 2010, Hematology/oncology clinics of North America.

[21]  Barbara Hero,et al.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Smith,et al.  Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration , 2019, JAMA pediatrics.

[23]  Thomas E. Nichols,et al.  HHS Public Access , 2018 .